Glucerna Bar

Drug overview for GLUCERNA BAR (nutritional therapy, glucose intolerance,soy):

Generic name: nutritional therapy, glucose intolerance,soy
Drug class:
Therapeutic class: Electrolyte Balance-Nutritional Products

No enhanced Introduction information available for this drug.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for GLUCERNA BAR (nutritional therapy, glucose intolerance,soy) have been approved by the FDA:

Indications:
None.

Professional Synonyms:
None.

The following drug interaction information is available for GLUCERNA BAR (nutritional therapy, glucose intolerance,soy):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 0 severe interactions.

There are 1 moderate interactions. The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.

Drug Interaction	Drug Names
Thyroid Preparations/Soybean Infant Formula; Nutritional Therapy SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Soy-based formula and nutritional therapy may bind to thyroid preparations, decreasing their absorption.(1-3) Also, many products may contain iron, which may also bind to thyroid preparations.(1) CLINICAL EFFECTS: Concurrent use of soy-based formula or nutritional therapy may result in increased TSH levels.(1-3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients receiving soy-based formula or nutritional therapy should be closely monitored for elevated TSH levels. The dosage of the thyroid preparation may need to increase during the use of soy-based products.(1-3) DISCUSSION: In a retrospective comparison of 78 infants with congenital hypothyroidism, 8 infants fed a soy-based formula had prolonged increase of TSH and time to TSH normalization, higher first TSH on treatment, and there was a larger percentage with increased TSH at 4 months of age when compared to 70 infants on a non-soy diet.(2) In a case report of 3 infants with congenital hypothyroidism, infants required 18-25% higher dosages of levothyroxine while receiving soy-based formulas.(3) In a case report, the administration of levothyroxine concurrently with a soy protein dietary supplement resulted in decreased absorption of levothyroxine and the need for higher oral doses of levothyroxine to attain therapeutic serum thyroid hormone levels.(4)	ADTHYZA, ARMOUR THYROID, CYTOMEL, EUTHYROX, EVEXITHROID, LEVO-T, LEVOTHYROXINE SODIUM, LEVOXYL, LIOMNY, LIOTHYRONINE SODIUM, NIVA THYROID, NP THYROID, PCCA T3 SODIUM DILUTION, RENTHYROID, SYNTHROID, THYQUIDITY, THYROID, TIROSINT, TIROSINT-SOL, UNITHROID

Drug Interaction

Drug Names

Thyroid Preparations/Soybean Infant Formula; Nutritional Therapy

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Soy-based formula and nutritional therapy may bind to thyroid preparations, decreasing their absorption.(1-3) Also, many products may contain iron, which may also bind to thyroid preparations.(1)

CLINICAL EFFECTS: Concurrent use of soy-based formula or nutritional therapy may result in increased TSH levels.(1-3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Patients receiving soy-based formula or nutritional therapy should be closely monitored for elevated TSH levels. The dosage of the thyroid preparation may need to increase during the use of soy-based products.(1-3)

DISCUSSION: In a retrospective comparison of 78 infants with congenital hypothyroidism, 8 infants fed a soy-based formula had prolonged increase of TSH and time to TSH normalization, higher first TSH on treatment, and there was a larger percentage with increased TSH at 4 months of age when compared to 70 infants on a non-soy diet.(2) In a case report of 3 infants with congenital hypothyroidism, infants required 18-25% higher dosages of levothyroxine while receiving soy-based formulas.(3) In a case report, the administration of levothyroxine concurrently with a soy protein dietary supplement resulted in decreased absorption of levothyroxine and the need for higher oral doses of levothyroxine to attain therapeutic serum thyroid hormone levels.(4)

ADTHYZA, ARMOUR THYROID, CYTOMEL, EUTHYROX, EVEXITHROID, LEVO-T, LEVOTHYROXINE SODIUM, LEVOXYL, LIOMNY, LIOTHYRONINE SODIUM, NIVA THYROID, NP THYROID, PCCA T3 SODIUM DILUTION, RENTHYROID, SYNTHROID, THYQUIDITY, THYROID, TIROSINT, TIROSINT-SOL, UNITHROID

The following precautions are available for GLUCERNA BAR (nutritional therapy, glucose intolerance,soy):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.